01612 VINCENT MED
- 0.380
- -0.005-1.30%
VINCENT MED News
永勝醫療：2023年年報
Earnings Beat: Vincent Medical Holdings Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
It's been a good week for Vincent Medical Holdings Limited (HKG:1612) shareholders, because the company has just released its latest yearly results, and the shares gained 5.3% to HK$0.40. Result
Vincent Medical Swings to Profit in 2023 as Revenue Jumps 14%
Vincent Medical Holdings (HKG:1612) reported a consolidated attributable net profit of HK$57.3 million for 2023, as opposed to a loss of HK$17.4 million in the preceding year, according to a filing wi
VINCENT MED To Go Ex-Dividend On May 28th, 2024 With 0.015 HKD Dividend Per Share
March 21st - $VINCENT MED(01612.HK)$ is trading ex-dividend on May 28th, 2024. Shareholders of record on May 29th, 2024 will receive 0.015 HKD dividend per share on June 21st, 2024. The ex-dividen
Yongsheng Medical (01612) will pay a final dividend of HK$0.015 per share on June 21
According to the Zhitong Finance App, Yongsheng Healthcare (01612) announced that it will pay a final dividend of HK$0.015 per share for the year ended 31 December 2023 on June 21, 2024.
Yongsheng Medical (01612.HK) turned an annual loss into a profit of HK$57.3 million with a final interest of HK1.5 cents
On March 20, GLONGHUI | Yongsheng Medical (01612.HK) announced that for the year ended December 31, 2023, the company's revenue achieved a steady organic increase of 14.1% to HK$718.0 million. Among them, the disposable imaging products segment increased by 20.0% and the respiratory products segment by 9.6%. The Group turned a loss into a profit in 2023. The consolidated net loss attributable to the owners of the company was HK$17.4 million for the year ended 31 December 2022, reversing the loss and recording a comprehensive profit of HK$57.3 million attributable to the company owner in the current year. Although the new integrated production facility is expected to generate capital
VINCENT MED: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023, RECOMMENDATION FOR DECLARATION OF FINAL DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS
Yongsheng Medical (01612.HK) plans to hold a board meeting on March 20 to approve annual results
Gelonghui, March 5, 丨 Yongsheng Medical (01612.HK) announced that the company will hold a board meeting on March 20, 2024 (Wednesday) to consider and approve the final results of the company and its subsidiaries for the year ended 31 December 2023, publish relevant final results, and pay a final dividend (if any).
VINCENT MED: DATE OF BOARD MEETING
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Vincent Medical Forecasts Swing to 2023 Profit
Vincent Medical Holdings (HKG:1612) expects an attributable profit of at least HK$52 million for the year ended Dec. 31, 2023, as compared to an attributable loss of HK$17.4 million in 2022. The medic
Yongsheng Medical (01612.HK) Yingxi: Expected annual net profit of not less than HK$52 million
Gelonghui, January 26, 丨 Yongsheng Medical (01612.HK) announced that for the year ended December 31, 2023, the Group expects to record a comprehensive profit of not less than HK$52 million for the year ended 31 December 2023, while for the year ended 31 December 2022, a comprehensive loss attributable to the owners of the audited company was approximately HK$17.4 million.
VINCENT MED: POSITIVE PROFIT ALERT
Yongsheng Medical (01612.HK) received 46,000 additional shares of common shares by Cai Zhangtai, worth approximately HK$17,900
On January 18, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 18, Choi Cheung-tai increased his common stock holdings of $Yongsheng Healthcare (01612.HK) by $46,000 at an average price of HK$0.3896 per share on January 17, worth about HK$17,900. After the increase in holdings, Cai Zhangtai's latest shareholding was 11.7 million shares, and the good position ratio increased from 1.78% to 1.79%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Listed company's
Yongsheng Medical (01612.HK) received an increase of 20,000 common shares by Choi Cheung-tai, worth approximately HK$7,600
On January 18, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 18, Choi Cheung-tai increased his common share holdings of $Yongsheng Medical (01612.HK) by $20,000 at an average price of HK$0.38 per share on January 16, worth about HK$7,600. After the increase in holdings, Cai Zhangtai's latest shareholding was 11.654 million shares, with a good position ratio of 1.78%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Directors and top executives of listed companies
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Yongsheng Medical (01612.HK) was increased by 170,000 shares by Chairman and Executive Director Cai Wencheng
Glonghui, December 29丨According to the latest equity disclosure data of the Stock Exchange, on December 27, 2023, Yongsheng Medical (01612.HK) was granted an increase of 170,000 shares by Chairman and Executive Director Cai Wencheng at an average price of HK$0.4012 per share on the market, involving approximately HK$68,200. After the increase in holdings, Cai Wencheng's latest shareholding was 393,189,890 shares, and the shareholding ratio increased from 60.16% to 60.18%.
Yongsheng Medical (01612.HK) obtained Cai Wencheng's additional common shares by 170,000 shares, worth approximately HK$68,200
On December 28, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on December 28, Tsai Man-shing increased his common share holdings of $Yongsheng Healthcare (01612.HK) by $170,000 at an average price of HK$0.4012 per share on December 27, worth about HK$68,200. After the increase in holdings, Cai Wencheng's latest shareholding was 393 million shares, and the good position ratio increased from 60.16% to 60.18%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. public
Analysis
Price Target
No Data
